Mirikizumab is a medication being studied for its effects on ulcerative colitis, which is a condition that causes inflammation and sores in the colon and rectum. This medication works by targeting a specific protein in the body that is involved in the inflammatory process. By blocking this protein, Mirikizumab aims to reduce inflammation and help improve symptoms such as bowel urgency, which is a sudden and strong need to have a bowel movement. The goal of using Mirikizumab in this trial is to see if it can help people with moderately to severely active ulcerative colitis feel better by reducing the severity of their symptoms.

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon, also known as the large intestine. It is characterized by inflammation and ulceration of the innermost lining of the colon, leading to symptoms such as abdominal pain, diarrhea, and rectal bleeding. The disease typically begins in the rectum and may extend continuously to involve the entire colon. The inflammation causes the colon to empty frequently, resulting in urgent bowel movements. Over time, the persistent inflammation can lead to the formation of ulcers, which are small open sores that can bleed and produce pus. The severity of symptoms can vary, with periods of active disease followed by times of remission.